Timing the emergence of resistance to anti-HIV drugs with large genetic barriers

PLoS Computational Biology

Volumn 5, Issue 3, 2009, Pages

  Arora, Pankhuri ^a   Dixit, Narendra M ^a  

^a INDIAN INSTITUTE OF SCIENCE   (India)

Author keywords

[No Author keywords available]

Indexed keywords

FORECASTING; GENES; STOCHASTIC SYSTEMS; TIMING CIRCUITS;

'CURRENT; ANTI-HIV; ANTIRETROVIRAL DRUGS; DARUNAVIR; HIV DYNAMICS; HIV INFECTION; HIV-1 PROTEASE; MODEL PREDICTION; OPTIMAL TREATMENT; TIPRANAVIR;

DYNAMICS;

HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; TIPRANAVIR; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ARTICLE; CONTROLLED STUDY; GENETIC RESISTANCE; GENOMICS; HUMAN IMMUNODEFICIENCY VIRUS; IN VITRO STUDY; NONHUMAN; VIRUS GENE; ANTIVIRAL RESISTANCE; BIOLOGICAL MODEL; COMPUTER SIMULATION; DRUG EFFECT; GENETIC VARIABILITY; GENETICS; MUTATION; TIME; VIRION; VIRUS ACTIVATION; VIRUS GENOME;

HUMAN IMMUNODEFICIENCY VIRUS 1;

ANTI-HIV AGENTS; COMPUTER SIMULATION; DRUG RESISTANCE, VIRAL; GENETIC VARIATION; GENOME, VIRAL; HIV; MODELS, GENETIC; MUTATION; TIME FACTORS; VIRION; VIRUS ACTIVATION;

EID: 63549107608     PISSN: 1553734X     EISSN: 15537358     Source Type: Journal    
DOI: 10.1371/journal.pcbi.1000305     Document Type: Article

References (52)

1. Clavel F, Hance AJ (2004) HIV drug resistance. N Engl J Med 350: 1023-1035.
2. Johnson VA, Brun-Vezinet F, Clotet B, Gunthard HF, Kuritzkes DR, et al. (2008) Update of the drug resistance mutations in HIV-1: Spring 2008. Top HIV Med 16: 62-68.
3. Perelson AS, Neumann AU, Markowitz M, Leonard JM, Ho DD (1996) HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science 271: 1582-1586.
4. Mansky LM, Temin HM (1995) Lower in-vivo mutation-rate of humanimmunodeficiency- virus type-1 than that predicted from the fidelity of purified reverse-transcriptase. J Virol 69: 5087-5094.
5. Jetzt AE, Yu H, Klarmann GJ, Ron Y, Preston BD, et al. (2000) High rate of recombination throughout the human immunodeficiency virus type 1 genome. J Virol 74: 1234-1240.
6. Rhodes T, Wargo H, Hu W-S (2003) High rates of human immunodeficiency virus type 1 recombination: Near-random segregation of markers one kilobase apart in one round of viral replication. J Virol 77: 11193-11200.
7. Levy DN, Aldrovandi GM, Kutsch O, Shaw GM (2004) Dynamics of HIV-1 recombination in its natural target cells. Proc Natl Acad Sci U S A 101: 4204-4209.
8. Wilkin TJ, Taylor B, Olender S, Hammer SM (2008) Advances in antiretroviral therapy. Top HIV Med 16: 31-60.
9. Hammer SM, Eron JJ, Reiss P, Schooley RT, Thompson MA, et al. (2008) Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. JAMA 300: 555-570.
10. Doyon L, Tremblay S, Bourgon L,Wardrop E, Cordingley MG (2005) Selection and characterization of HIV-1 showing reduced susceptibility to the nonpeptidic protease inhibitor tipranavir. Antiviral Res 68: 27-35.
11. de Meyer S, Vangeneugden T, van Baelen B, de Paepe E, van Marck H, et al. (2008) Resistance profile of darunavir: Combined 24-week results from the POWER trials. AIDS Res Hum Retroviruses 24: 379-388.
12. Shafer RW, Schapiro JM (2005) Drug resistance and antiretroviral drug development. J Antimicrob Chemother 55: 817-820.
13. Lapadula G, Izzo I, Gargiulo F, Paraninfo G, Castelnuovo F, et al. (2008) Updated prevalence of genotypic resistance among HIV-1 positive patients naive to antiretroviral therapy: a single center analysis. J Med Virol 80: 747-753.
14. Ribeiro RM, Bonhoeffer S, Nowak MA (1998) The frequency of resistant mutant virus before antiviral therapy. AIDS 12: 461-465.
15. Delfraissy JFO, Flandre P, Delaugerre C, Ghosn J, Horban A, et al. (2008) Lopinavir/ritonavir monotherapy or plus zidovudine and lamivudine in antiretroviral-naive HIV-infected patients. AIDS 22: 385-393.
16. Riddler SA, Haubrich R, DiRienzo AG, Peeples L, Powderly WG, et al. (2008) Class-sparing regimens for initial treatment of HIV-1 infection. N Engl J Med 358: 2095-2106.
17. Moyle G, Higgs C, Teague A, Mandalia S, Nelson M, et al. (2006) An openlabel, randomized comparative pilot study of a single-class quadruple therapy regimen versus a 2-class triple therapy regimen for individuals initiating antiretroviral therapy. Antivir Ther 11: 73-78.
18. Kuritzkes DR (2004) Preventing and managing antiretroviral drug resistance. AIDS Patient Care STDS 18: 259-273.
19. Shuter J, Sarlo JA, Kanmaz TJ, Rode RA, Zingman BS (2007) HIV-infected patients receiving lopinavir/ritonavir-based antiretroviral therapy achieve high rates of virologic suppression despite adherence rates less than 95%. J Acquir Immun Defic Syndr 45: 4-8.
20. Perno CF, Moyle G, Tsoukas C, Ratanasuwan W, Gatell J, et al. (2008) Overcoming resistance to existing therapies in HIV-infected patients: the role of new antiretroviral drugs. J Med Virol 80: 565-576.
21. Larder BA, Hertogs K, Bloor S, van den Eynde C, DeCian W, et al. (2000) Tipranavir inhibits broadly protease inhibitor-resistant HIV-1 clinical samples. AIDS 14: 1943-1948.
22. Martinez-Cajas JL, Wainberg MA (2008) Antiretroviral therapy: optimal sequencing of therapy to avoid resistance. Drugs 68: 43-72.
23. Baxter JD, Schapiro JM, Boucher CAB, Kohlbrenner VM, Hall DB, et al. (2006) Genotypic changes in human immunodeficiency virus type 1 protease associated with reduced susceptibility and virologic response to the protease inhibitor tipranavir. J Virol 80: 10794-10801.
24. Kouyos RD, Althaus CL, Bonhoeffer S (2006) Stochastic or deterministic: what is the effective population size of HIV-1? Trends Microbiol 14: 507-511.
25. Moutouh L, Corbeil J, Richman DD (1996) Recombination leads to the rapid emergence of HIV-1 dually resistant mutants under selective drug pressure. Proc Natl Acad Sci U S A 93: 6106-6111.
26. Nora T, Charpentier C, Tenaillon O, Hoede C, Clavel F, et al. (2007) Contribution of recombination to the evolution of human immunodeficiency viruses expressing resistance to antiretroviral treatment. J Virol 81: 7620-7628.
27. Bretscher MT, Althaus CL, Muller V, Bonhoeffer S (2004) Recombination in HIV and the evolution of drug resistance: for better or for worse? Bioessays 26: 180-188.
28. Althaus CL, Bonhoeffer S (2005) Stochastic interplay between mutation and recombination during the acquisition of drug resistance mutations in human immunodeficiency virus type 1. J Virol 79: 13572-13578.
29. Bocharov G, Ford NJ, Edwards J, Breinig T, Wain-Hobson S, et al. (2005) A genetic-algorithm approach to simulating human immunodeficiency virus evolution reveals the strong impact of multiply infected cells and recombination. J Gen Virol 86: 3109-3118.
30. Fraser C (2005) HIV recombination: what is the impact on antiretroviral therapy? J R Soc Interface 2: 489-503.
31. Gheorghiu-Svirschevski S, Rouzine IM, Coffin JM (2007) Increasing sequence correlation limits the efficiency of recombination in a multisite evolution model. Mol Biol Evol 24: 574-586.
32. Vijay NNV, Vasantika, Ajmani R, Perelson AS, Dixit NM (2008) Recombination increases HIV fitness but not necessarily diversity. J Gen Virol 89: 1467-1477.
33. Dixit NM (2008) Modelling HIV infection dynamics: The role of recombination in the development of drug resistance. Future HIV Ther 2: 375-388.
34. Nowak MA, May RM (2000) Virus Dynamics: Mathematical Principles of Immunology and Virology. New York: Oxford University Press.
35. Perelson AS (2002) Modelling viral and immune system dynamics. Nat Rev Immunol 2: 28-36.
36. Muller V, Bonhoeffer S (2003) Mathematical approaches in the study of viral kinetics and drug resistance in HIV-1 infection. Curr Drug Targets Infect Disord 3: 329-344.
37. Suryavanshi GW, Dixit NM (2007) Emergence of recombinant forms of HIV: dynamics and scaling. PLoS Comput Biol 3: e205. doi:10.1371/journal. pcbi.0030205.
38. Martinez-Cajas JL, Wainberg MA (2007) Protease inhibitor resistance in HIVinfected patients: molecular and clinical perspectives. Antiviral Res 76: 203-221.
39. Dixit NM, Perelson AS (2005) HIV dynamics with multiple infections of target cells. Proc Natl Acad Sci U S A 102: 8198-8203.
40. Rhodes TD, Nikolaitchik O, Chen JB, Powell D, Hu WS (2005) Genetic recombination of human immunodeficiency virus type 1 in one round of viral replication: effects of genetic distance, target cells, accessory genes, and lack of high negative interference in crossover events. J Virol 79: 1666-1677.
41. Christiansen FB, Otto SP, Bergman A, Feldman MW (1998) Waiting with and without recombination: the time to production of a double mutant. Theor Popul Biol 53: 199-215.
42. Ribeiro RM, Bonhoeffer S (2000) Production of resistant HIV mutants during antiretroviral therapy. Proc Natl Acad Sci U S A 97: 7681-7686.
43. Yin P, Das D, Mitsuya H (2006) Overcoming HIV drug resistance through rational drug design based on molecular, biochemical, and structural profiles of HIV resistance. Cell Mol Life Sci 63: 1706-1724.
44. Jung A, Maier R, Vartanian JP, Bocharov G, Jung V, et al. (2002) Multiply infected spleen cells in HIV patients. Nature 418: 144-144.
45. Sato H, Orenstein J, Dimitrov D, Martin M (1992) Cell-to-cell spread of HIV-1 occurs within minutes and may not involve the participation of virus-particles. Virology 186: 712-724.
46. Dixit NM, Perelson AS (2004) Multiplicity of human immunodeficiency virus infections in lymphoid tissue. J Virol 78: 8942-8945.
47. Chen BK, Gandhi RT, Baltimore D (1996) CD4 down-modulation during infection of human T cells with human immunodeficiency virus type 1 involves independent activities of vpu, env, and nef. J Virol 70: 6044-6053.
48. Piguet V, Gu F, Foti M, Demaurex N, Gruenberg J, et al. (1999) Nef-induced CD4 degradation: a diacidic-based motif in Nef functions as a lysosomal targeting signal through the binding of b-COP in endosomes. Cell 97: 63-73.
49. Ross SM (2007) Introduction to Probability Models. San Diego, California: Academic Press.
50. Boerlijst MC, Bonhoeffer S, Nowak MA (1996) Viral quasi-species and recombination. Proc R Soc Lond B Biol Sci 263: 1577-1584.
51. Gabrielson J, Weiner D (2000) Pharmacokinetic and Pharmacodynamic Data Analysis: Concepts and Applications. Stockholm, Sweden: Apotekarsocieteten.
52. Speirs C, van Nimwegen E, Bolton D, Zavolan M, Duvall M, et al. (2005) Analysis of human immunodeficiency virus cytopathicity by using a new method for quantitating viral dynamics in cell culture. J Virol 79: 4025-4032